732302-99-7 Usage
Description
Givinostat (ITF2357) is a histone deacetylase (HDAC) inhibitor with a potent IC50 of 7.5-16 nM. It is a pharmaceutical compound that modulates the acetylation of histone proteins, which play a crucial role in the regulation of gene expression. Givinostat has shown potential in the treatment of various diseases by targeting the epigenetic mechanisms involved in their pathogenesis.
Uses
Used in Muscular Dystrophy Treatment:
Givinostat (ITF2357) is used as a therapeutic agent for the treatment of muscular dystrophy. It modulates the acetylation of histone proteins, which can lead to the upregulation of genes involved in muscle repair and function, thereby potentially improving muscle strength and reducing the progression of the disease.
Used in HIV Research:
Givinostat hydrochloride hydrate has been utilized as a histone deacetylase inhibitor in research settings to study its effect on human immunodeficiency virus (HIV) reactivation in CD4+ T-cell models. By inhibiting HDACs, Givinostat can potentially influence the expression of genes involved in HIV latency and reactivation, providing valuable insights into the development of novel therapeutic strategies for HIV treatment and eradication.
Biological Activity
itf2357, also known as givinostat, is a potent inhibitor of both class i and class ii histone deacetylase (hdac) as well as a potent inhibitor of hematopoietic colony formation by jakev617f-bearing progenitor cells from chronic myeloproliferative neoplasms in vitro. previous studies has shown that itf2357 induces apoptosis of multiple myeloma (mm) and acute myelogenous leukemia (aml) cells following induction of p21 and down-modulation of bcl-2 and mcl-1 proteins and inhibits the production of pro-inflammatory cytokines (such as il-1, il-6, tumor necrosis factor (tnf)-α and interferon (ifn)-γ) by peripheral blood mononuclear cells as well as the production of il-6 and vascular endothelium growth factor (vegf) by mesenchymal stromal cells.katia todoerti, valentina barbui, olga pedrini, marta linett, gianluca fossati, paolo mascagni, alessandro rambaldi, antonino neri, martino introna, luigia lombardi, and josee golay. pleiotropi anti-myeloma activity of itf2357: inhibition of interleukin-6 receptor signaling and repression of mir-19a and mir-19b. haematologica 2010; 95(2): 260-269
Biochem/physiol Actions
Givinostat (ITF2357) is a hydroxamate HDAC inhibitor that inhibits class I and class II enzymes. Givinostat posseses a very promising activity profile in multiple myeloma and acute myelogenous leukemia in vitro and in vivo. Givinostat also has anti-inflammatory activity and inhibits the secretion of the tumor necrosis factor-alpha (TNF-α), IL-1, and IL-6. Givinostat has been in multiple Phase 2 studies for both inflammatory diseases (Duchenne Muscular Dystrophy , Juvenile arthritis, Polycythemia Vera) and blood cancers (myelomas and lymphomas).
Check Digit Verification of cas no
The CAS Registry Mumber 732302-99-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,3,2,3,0 and 2 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 732302-99:
(8*7)+(7*3)+(6*2)+(5*3)+(4*0)+(3*2)+(2*9)+(1*9)=137
137 % 10 = 7
So 732302-99-7 is a valid CAS Registry Number.
